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Antineoplastic drug induced nausea and vomiting (AINV) is a major adverse event which deeply impacts
the quality of life of children with cancer. It additionally causes distress to parents and negatively impacts
compliance to therapy. A robust AINV prophylaxis regimen is essential to achieve complete control; and
prevent anticipatory, breakthrough and refractory AINV. With a wide array of available anti-emetics,
standard guidelines for their use are crucial to ensure uniform and optimum prophylaxis. Chemother-
apeutic agents are classiﬁed as having high, moderate, low or minimal emetic risk based on their po-
tential to cause emesis in the absence of prophylaxis. Three drug regimen with aprepitant, ondansetron/
granisetron and dexamethasone is recommended for protocols with high emetic risk. Although approved
in children 12 years, there is mounting evidence for the use of aprepitant in younger children too. In
protocols with moderate and low emetic risk, combination of ondansetron/granisetron and dexameth-
asone; and single agent ondansetron/granisetron are recommended, respectively. Metoclopramide is an
alternative when steroids are contraindicated. Olanzapine and lorazepam are useful drugs for break-
through AINV and anticipatory AINV. Knowledge of pediatric dosage, salient adverse events, drug in-
teractions as well as cost of drugs is essential to prescribe anti-emetics accurately and safely in resource
constrained settings. Non pharmacological interventions such as hypnosis, acupressure and psycholog-
ical interventions can beneﬁt a sub-group of patients without signiﬁcant risk of adverse events.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Antineoplastic drug induced nausea and vomiting (AINV) con-
stitutes an undesirable adverse event which profoundly impacts
the quality of life of children with cancer, as well as their caregivers
[1e3]. The entity is also referred to as chemotherapy induced
nausea and vomiting [2e4]. Additionally, it can compromise
compliance to chemotherapy and disease free survival [2,3]. AINV is
best prevented with an optimal antiemetic regimen [3]. Inadequate
control often leads to a vicious cycle of breakthrough, anticipatory
and sometimes refractory AINV [3e5]. Uncontrolled vomiting can
result in potentially life threatening complications such as dehy-
dration, dyselectrolytemias, aspiration pneumonia, wound dehis-
cence, upper gastrointestinal tract injury/bleeding, malnutrition
and psychological stress [3,6,7]. In resource limited settings, AINVatology Oncology Chapter of
apter of Indian Academy of Pediat
enses/by-nc-nd/4.0/).further adds to the cost of therapy, increased need of hospital visits
and prolongation of hospital stay [3].
2. Literature review
There is a paucity of guidelines for anti-emetic prophylaxis in
children with cancer. The American Society of Clinical Oncology
published updated clinical practice guidelines in 2011 followed by a
focused clinical update in 2015 [8,9]. However, these do not spe-
ciﬁcally address pediatric patients [8,9]. The Pediatric Oncology
Group of Ontario (POGO) published a series of guidelines
addressing management of AINV in children. The ﬁrst outlined
classiﬁcation of antineoplastic agents based on their emetogenic
potential [10]. This was followed by guidelines for prevention of
acute AINV; prevention and treatment of anticipatory AINV; as well
as prevention and treatment of breakthrough and refractory AINV
[4,5,11]. These guidelines have been utilized as the backbone of this
review. Further inputs regarding formulations available in the In-
dian market and their cost have been obtained from the current
index of medical specialties (CIMS) website [12].rics. Production and hosting by Elsevier B.V. This is an open access article under the
Table 1
Classiﬁcation of chemotherapeutic agents based on their emetogenicity.
Category
(frequency of emesis in
the absence of antiemetic
prophylaxis in %)
Chemotherapeutic agents
Highly emetic
(>90%)
Cisplatin, carboplatin
Cyclophosphamide  1 g/m2
Dacarbazine
Actinomycin-D
Methotrexate  12 g/m2
Cyclophosphamide þ Anthracycline
Cyclophosphamide þ Etoposide
Cytarabine 150e200 mg/m2 þ Daunorubicin
Cytarabine 300 mg/m2 þ Etoposide
Doxorubicin þ Ifosfamide
Doxorubicin þ Methotrexate 5 g/m2
Etoposide þ Ifosfamide
Oral: Procarbazine
Moderately emetic
(30e90%)
Arsenic trioxide
Busulfan
Carmustine  250 mg/m2
Cyclophosphamide < 1 g/m2, Ifosfamide
Cytarabine > 200 mg/m2 to < 3 g/m2
Daunorubicin, doxorubicin, idarubicin,
epirubicin
IT therapy (Methotrexate, hydrocortisone,
cytarabine)
Irinotecan
Lomustine
Melphalan > 50 mg/m2
Methotrexate  250 mg/m2 to < 12 g/m2
Oral: Cyclophosphamide, etoposide,
temozolomide, imatinib
Low level emetic
(10 to < 30%)
Cytarabine  200 mg/m2
Etoposide
5-Fluorouracil
Gemcitabine
Methotrexate > 50 mg/m2 to < 250 mg/m2
Mitoxantrone
Topotecan
Oral: Busulfan
Minimally emetic
(<10%)
L-Asparaginase (IM and IV)
Bevacizumab
Bleomycin
Cladribine
Fludarabine
Methotrexate  50 mg/m2
Nelarabine
Rituximab
Vincristine, vinblastine, vindesine, vinorelbine
Oral: 6-MP, 6-TG, dasatinib, hydroxyurea,
sorafenib
Drugs to be assumed as intravenously administered unless speciﬁed otherwise; IT:
Intrathecal; IM: Intramuscular; IV: Intravenous; 6-MP: 6-mercaptopurine; 6-TG:
6-thioguanine. Adapted from: Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R,
McCarthy P et al. Guideline for the classiﬁcation of the acute emetogenic potential
of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer.
2011 Aug; 57(2):191e8.
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Acute AINV is deﬁned as nausea, vomiting and/or retching
occurring within 24 h of administration of chemotherapy. Acute
AINV excludes delayed, anticipatory or breakthrough AINV; as well
as nausea/vomiting secondary to other therapeutic modalities such
as radiotherapy and palliative medications, primary disease and co-
incident conditions [7,11]. Delayed AINV occurs after 24 h of
administration, and usually within 7 days [7]. AINV ensuing in any
phase despite adequate antiemetic prophylaxis with the usual
standard of care is termed breakthrough [4,7]. Refractory AINV fails
to respond to changing prophylaxis or treatment [4]. Further,
nausea/vomiting may develop within 24 h prior to antineoplastic
therapy, termed as anticipatory AINV [5,7]. Optimum control of
AINV is identiﬁed by absence of nausea, vomiting, retching and
AINV induced anorexia; from start of the chemotherapy block till
24 h after administration of last chemotherapeutic agent; without
requirement of additional anti-emetics outside the prescribed
prophylaxis [11].
The ﬁrst step in prescribing an antiemetic regimen for pre-
venting AINV entails assessment of the emetogenic potential of the
chemotherapy scheduled to be administered [10]. Emetic risk is
measured by the frequency of emesis in the absence of prophylaxis
[10]. Based on emetic risk, chemotherapeutic agents are classiﬁed
as: highly emetogenic chemotherapy (HEC) if risk > 90%, moder-
ately emetogenic chemotherapy (MEC) if risk 30e90%, chemo-
therapy with low emetic risk (LEC) if 10e30% and minimally
emetogenic chemotherapy if < 10% [10]. Table 1 illustrates the
emetogenic potential of chemotherapeutic agents commonly used
in the day to day practice of pediatric oncology. Besides emetoge-
nicity of antineoplastic therapy, additional risk factors for AINV
include older age (>3 years), female gender and prior history of
AINV [3]. It is evident from this classiﬁcation that almost all treat-
ment protocols administered in pediatric malignancies such as
sarcomas, Wilms tumor, neuroblastoma, hepatoblastoma, medul-
loblastoma, lymphomas and myeloid leukemia possess high emetic
risk. Chemotherapy administered during the intensive phases of
management of acute lymphoblastic leukemia which include
anthracyclines, cyclophosphamide and high dose methotrexate
would qualify as at least moderately emetic. This reiterates the
importance of AINV prophylaxis in pediatric oncology.
A multi-national cross sectional survey of children and adults
with cancer receiving chemotherapy/radiotherapy revealed that
physicians/nurses may signiﬁcantly underestimate the impact of
AINV on the quality of life of patients [13]. While 76% physicians
adhered to guidelines while prescribing anti-emetics in HEC,
merely 15% followed guidelines for MEC [13]. Lesser than 40% pa-
tients reported complete adherence to self-administered anti-
emetic drugs as advised by their physician/nurse [13]. This un-
derscores the importance of thorough understanding of current
recommendations by physicians/nurses; as well as the need for
reinforcement of compliance to anti-emetic drugs among patients
and their caregivers.4. Antiemetic armamentarium in children
AINV results from the stimulation of the centrally located emetic
center and chemoreceptor trigger zone in the brain as well as the
peripherally located vagal afferents in the gastrointestinal tract [14].
The mediators and respective receptors involved in this process
include dopamine acting on dopamine receptor D2; serotonin
acting on 5-hydroxytryptamine receptor 5-HT3; prostaglandins;
and substance P acting on Neurokinin (NK-1) receptors [3,14].Cholinergic, cannabinoid (CB-1) and a-adrenergic receptors are
additional receptors involved in the emetic mechanism [3,14].
Consequently, antiemetic drugs have been developed to target these
receptors. Classiﬁcation of these drugs based on their mechanism of
action, and adverse events are outlined in Table 2. Dosing schedules
and cost of commonly used drugs are described in Table 3.
5. Anti-emetic prophylaxis for AINV: case based approach
5.1. Anti-emetic prophylaxis for acute AINV
Case 1. A 7-year-old girl with weight of 19 kg and body surface area
(BSA) of 0.76 was diagnosed with non-metastatic Ewing sarcoma of
Table 3
Dosing schedule and cost of commonly used anti-emetic drugs.
Name Dose Available formulations with approximate maximum retail
price in Indian market
Ondansetron 5 mg/m2/dose IV/PO q 8e12 hourly (max. 8 mg/dose) in HEC/
MEC
10 mg/m2 IV/PO stat dose in LEC
Tab. 4 mg  10 e Rs 50
Syr. 2 mg/5 ml  30 ml e Rs 35
Inj. 2 mg/ml  4 ml e Rs 30
Granisetron 40 mg/kg PO q 12 hourly (or)
40 mg/kg IV q 24 hourly in HEC/MEC/LEC (max. 3 mg/dose)
Tab. 1 mg  4 e Rs 80
Syr. 1 mg/5 ml  30 ml e Rs 35
Inj. 1 mg/ml  3 ml e Rs 60
Palonosetron 20 mg/kg IV stat (max. 1.5 mg) Inj. 0.25 mg/5 ml  5 ml e Rs 140
Aprepitant 125 mg PO on day1, 80 mg on days 2 & 3, q 24 hourly in HEC* Blister pack of 3 capsules (125 mg  1 and 80 mg  2) e Rs
1215
Dexamethasone# 6 mg/m2/dose IV/PO q 6 hourly in HEC, 2 mg (BSA < 0.6) or 4 mg
(BSA  0.6) IV/PO q 12 hourly in MEC
Tab. 4 mg  4 e Rs 16
Inj. 4 mg/ml  2 ml e Rs 8
Metoclopromide 1e5 mg IV/PO q 8 hourly in settings where steroids are not
permitted
Tab. 5 mg  10 e Rs 8
Syr. 1 mg/ml  30 ml e Rs 20
Inj. 5 mg/ml  10 ml e Rs 12
Olanzapine 0.1 mg/kg PO q 24 hourly (max. 10 mg) in breakthrough AINV Tab. 5 mg  10 e Rs 50
Lorazepam 0.04e0.08 mg/kg PO (max. 2 mg) night prior and morning of
chemo for anticipatory AINV
Tab. 2 mg  10 e Rs 25
IV: intravenous; PO: per oral; HEC: highly emetogenic chemotherapy; MEC: moderately emetogenic chemotherapy; LEC: chemotherapy with low emetic risk; Tab: Tablet; Inj:
Injection; Rs: Rupees; *Consider dose of 80 mg on all 3 days if age <12 years and weight 15e40 kg; #50% dose dexamethasone if simultaneously giving aprepitant.
Table 2
Anti-emetics available for use in children with their pharmacological proﬁle.
Class of drugs based on mechanism of action Drugs available Adverse events
5HT3 receptor antagonists Ondansetron
Granisetron
Palonosetron
Mild headache, ﬂushing, constipation, QT prolongation
NK-1 antagonists Aprepitant
Fosaprepitant
Constipation, fatigue, diarrhea, Inhibition of cytochrome P-
450 leading to drug interactions
Corticosteroids (Inhibition of prostaglandin synthesis in
hypothalamus)
Dexamethasone Hyperglycemia, epigastric pain, sleep disturbance
Dopamine antagonists Metoclopromide
Chlorpromazine
Levomepromazine
Sedation, akathisia, acute dystonic reactions
Benzodiazepines (Sedation, anxiolysis, depression of emetic
center)
Lorazepam Respiratory depression, hypotension, syncope, dependency
Cannabinoids Dronabinol
Nabilone
Dizziness, sedation, dysphoria, hypotension, hallucinations
5-HT3: 5 hydroxytryptamine3; NK-1: Neurokinin-1.
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cycle comprising vincristine (1.5 mg/m2), cyclophosphamide (1.2 g/m2)
and doxorubicin (50 mg/m2). What would be the ideal antiemetic
schedule for AINV prophylaxis?
5.1.1. Prophylaxis for acute AINV in chemotherapy regimens with
high emetic risk (HEC)
The child described in Case 1 is about to receive a HEC as it
contains cyclophosphamide in combination with doxorubicin. The
emetic risk of a multi-agent chemotherapy block is contributed by
the most emetogenic single drug or combination of drugs as illus-
trated in Table 1 [8,10]. Further in multiple day schedules, the risk
for each day would be contributed by the most emetogenic single
drug/drug combination administered on that day [8,10]. The POGO
guideline for acute AINV prophylaxis recommends a combination of
three drugs: aprepitant, dexamethasone and 5HT3-receptor
antagonist (ondansetron/granisetron) for HEC [11]. In children
aged <12 years in whom aprepitant is not currently approved, as
well as patients receiving chemotherapeutic drugs which have the
potential to interact with aprepitant (See Table 2), dexamethasone
and ondansetron/granisetron alone are recommended [11]. The
ASCO guideline recommends aprepitant/5-HT3-receptor blocker/
dexamethasone in adults for HEC [8,9]. However it continues to
recommend 5-HT3-receptor blocker/dexamethasone for pediatric
patients receiving HEC, with higher weight based dosing [8,9]. Formulti-day chemotherapy, anti-emetics appropriate for the emeto-
genic risk class of the chemotherapy are to be administered for each
day of the chemotherapyand for 2 days afterward, if appropriate [8].
Aprepitant is solely available as oral capsules of 125 mg and
80mg strength. Standard dose is 125 mg 1 h prior to chemotherapy
administration on day 1, followed by 80 mg once daily on the
morning of days 2 and 3 [11]. Dexamethasone is recommended at a
dose of 6 mg/m2 every 6 hourly administered orally (PO) or intra-
venous (IV) (dose halved if aprepitant is being used concomitantly,
as it doubles the area under the curve of dexamethasone) [11,15].
Ondansetron is administered at a dose of 5 mg/m2 (0.15 mg/kg) PO/
IV 30 min prior to chemotherapy followed by 8 hourly doses [11].
Alternatively, granisetron can replace ondansetron as a once daily
IV dose of 40 mg/kg [11]. Although, the guideline recommends
aprepitant in children aged >12 years, two recently published
randomized control trials (RCT) have shed new light on the use of
aprepitant in younger children [16,17]. Kang et al. performed a
multicenter phase-3 randomized control trial in 307 children aged
between 6months and 17 years [16]. Oral suspensions of aprepitant
were prepared for the trial, and doses of 3 mg/kg on day 1 and
2 mg/kg on day 2 were used in children aged <12 years, while
standard dose with 125 mg/80 mg capsules was used in older
children [16]. Complete response in the delayed phase was 51% as
compared to 26% in the control arm (p < 0.0001) [16]. Grade 3e4
events such as febrile neutropenia did not differ between the two
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aged 5e18 years [17]. Children weighing 15e40 kg were adminis-
tered 80 mg on all 3 days, while standard dosing was followed in
heavier children [17]. Complete response was 48% as compared to
12% in patients receiving ondansetron/dexamethasone alone
(p < 0.0001) with no increase in adverse events [17]. Currently
aprepitant is approved for all children older than 12 years as well as
those who are younger but weighing >30 kg and with ability to
swallow capsules [18].
With current evidence of superiority and safety of aprepitant as
prophylaxis for acute AINV in children, it may be prudent to offer
the drug in all children receiving HEC, who are old enough to
swallow capsules. As practiced by Bakhshi et al., 80mg dose on all 3
days can be utilized for younger childrenwhoweigh 15e40 kg [17].
Besides age, drug interactions potentially limit the use of aprepi-
tant. Aprepitant, being an inhibitor of the CYP3A4 isoenzyme, can
potentially interact with several antineoplastic drugs which are
metabolized by CYP3A4. These include vinca alkaloids, taxanes,
etoposide, irinotecan, ifosfamide, thiotepa and tyrosine kinase in-
hibitors such as imatinib and dasatinib [11,15]. However, the
following reasons offset the concern arising from such potential
interactions. Firstly, aprepitant induced CYP3A4 may be more
relevant for oral drugs rather than intravenously administered
drugs [15]. The enzyme inhibitory effect of aprepitant is moderate
and only marginally signiﬁcant in comparison to other inhibitors
such as rifampin and ketoconazole [15]. Further, there is paucity of
evidence demonstrating clinically signiﬁcant interaction between
aprepitant and the above mentioned antineoplastic drugs [15]. The
interaction of aprepitant with ifosfamide and cyclophosphamide is
noteworthy. While CYP3A4 does not play a major role in the
metabolism of cyclophosphamide, it is involved in the metabolism
and activation of ifosfamide. Therefore, while the former drug is not
affected by aprepitant, combination with ifosfamide is associated
with risk of precipitating neurotoxicity by interfering with its
metabolism [15,19,20]. ASCO guideline recommends use of apre-
pitant in all HEC protocols, in adults [8]. Other drugs which merit
caution while being simultaneously administered with aprepitant
include warfarin (requires close monitoring of international
normalized ratio for two weeks after aprepitant administration)
and oral contraceptives (necessitates secondary method of
contraception) [15]. Fosaprepitant, a single dose IV pro-drug which
has been approved in patients >18 years, is yet to be validated in
children.
Antiemetic schedule in Case 1: Capsule aprepitant 80 mg 1 h was
administered PO prior to chemotherapy on day 1, followed by 80 mg
once daily on days 2 and 3. Ondansetron 4 mg IV (5 mg  BSA 0.76)
was given 30 min prior to chemotherapy followed by 8 hourly doses
(Alternatively, granisetron 0.8 mg (40 mg  body weight 19 kg) can be
administered as a single dose). Dexamethasone 2 mg (6  BSA
0.76¼ 4mg, halved as aprepitant being given) was administered every
6 hourly.
5.1.2. Prophylaxis for acute AINV in chemotherapy regimens with
moderate emetic risk (MEC)
Case 2. An 8-year-old boy weighing 22 kg and having BSA of 0.84
receiving treatment for metastatic neuroblastoma failed to respond to
conventional chemotherapy and was planned for salvage chemo-
therapy with topotecan/cyclophosphamide regimen. The regimen
scheduled was as follows: topotecan (0.75 mg/m2/day) and cyclo-
phosphamide (250mg/m2/day) for 5 days. Plan antiemetic prophylaxis.
The regimen described in Case 2 is MEC (topotecan has low
emetic risk while cyclophosphamide daily dose of 250 mg/m2 has
moderate emetic risk). Recommended combination for MEC in-
cludes ondansetron/granisetron and dexamethasone [11]. This ismirrored by the ASCO guideline, which additionally mentions
palonosetron as the preferred 5-HT3-receptor blocker for MEC
[8,9]. Ondansetron is administered at a dose of 5 mg/m2 (0.15 mg/
kg) PO/IV 30 min prior to chemotherapy followed by 12 hourly
doses [11]. Alternatively, granisetron can replace ondansetron as a
once daily IV dose or twice daily oral dose of 40 mg/kg [11]. Dexa-
methasone is recommended at the following dose: 2 mg/dose IV/
PO q 12 hourly for BSA <0.6 and 4 mg/dose IV/PO q 12 hourly for
BSA 0.6 [11].
Antiemetic schedule in Case 2: Granisetron was administered as a
single daily dose of 0.9 mg (40 mg  body weight 22 kg) IV prior to
chemotherapy and dexamethasone was administered at a dose 4 mg
every 12 hourly (BSA > 0.6).
5.1.3. AINV prophylaxis in HEC/MEC where dexamethasone is
contraindicated
Case 3. A 2.5-year-old boy weighing 12 kg and BSA 0.54 with me-
dulloblastoma underwent complete resection of tumor. The pediatric
oncologist decided to proceed with chemotherapy as the child was too
young for craniospinal irradiation. The chemotherapy cycle scheduled
included cisplatin (3.5 mg/kg) on day 1; vincristine (0.05 mg/kg) on
days 1, 8, and 15; etoposide (4 mg/kg/d) followed by cyclophosphamide
(65 mg/kg/d) with mesna on days 2 and 3 and methotrexate (400 mg/
kg) on day 4 with leucovorin rescue. How should one go about charting
an antiemetic prophylaxis schedule?
Certain chemotherapy protocols discourage use of dexametha-
sone, such as those used in acute myeloid leukemia where steroids
can cause additional immunosuppression and increased invasive
fungal infections; and brain tumors where steroids can interfere
with distribution of chemotherapeutic drugs into the CNS
compartment [21]. Further, physician discretion, parental prefer-
ence, and steroid already being an integral component of the
chemotherapy regimen can inhibit the use of dexamethasone as an
antiemetic [21]. The POGO guideline recommends combination of
5HT3-receptor antagonist along with either of chlorpromazine/
nabilone for HEC and either of metoclopramide/chlorpromazine/
nabilone for MEC [11].
Chlorpromazine is recommended at a starting dose of 0.5 mg/kg
(may be increased up to 1mg/kg) IV every 6 hourly [11]. It is safer to
be administered in-patient due to risk of sedation and hypotension
[11]. Diphenhydramine/benztropine can be added to prevent
extrapyramidal effects [11]. Nabilone is an alternative drug for
combining with 5HT3 receptor blocker with the following dose:
<18 kg body weight: 0.5 mg/dose PO twice daily; 18e30 kg: 1 mg/
dose PO twice daily; >30 kg: 1 mg/dose PO three times daily
[Maximum daily dose: 0.06 mg/kg/day] [11]. Its use is however off
set by adverse effects such as dysphoria, dizziness and hallucina-
tions [14]. Metoclopramide is recommended for MEC rather than
HEC, as an RCT demonstrated superior control in low to moderate
emetic risk as compared to high risk (74% versus 11%) [22]. A meta-
analysis of studies evaluating pediatric use of metoclopramide
concluded that commonest adverse effects were extrapyramidal
symptoms, sedation and diarrhea which were completely revers-
ible [23]. Recommended dose in the POGO guideline is 1 mg/kg IV
pre-chemotherapy followed by 0.0375 mg/kg PO every 6 hourly
[11]. The author prefers to use metoclopramide over chlorproma-
zine and nabilone even in regimens with high emetic risk due to
paucity of experience of using chlorpromazine/nabilone in chil-
dren. The recommended dose in children is: 1e3 yr (10e14 kg)e
1 mg TDS; >3e5 yr (15e19 kg)e2 mg TDS; >5e9 yr (20e29 kg)e
2.5 mg TDS; >9e18 yr (30e60 kg): 5 mg TDS [maximum duration:
48 h] [24]. The POGO guideline discourages use of metoclopramide
in children aged less than 1 year due to concern of extrapyramidal
symptoms [4].
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cisplatin. Steroids were avoided as it was a CNS malignancy. Ondan-
setron was administered at a dose of 2.5 mg (5  BSA 0.54) IV prior to
chemotherapy on day 1 and 8 hourly subsequently. Metoclopramide
was administered at a dose of 1 mg TDS PO [as per CIMS dosing
recommendation].
5.1.4. Prophylaxis for AINV in chemotherapy regimens with low and
minimal emetic risk
Single agent prophylaxis with 5HT3-receptor antagonist is suf-
ﬁcient for chemotherapy with low emetic risk: ondansetron 10 mg/
m2 [0.3 mg/kg, maximum 16 mg/day] single dose IV/PO prior to
chemotherapy [8,11]. Granisetron can be used alternatively in the
same dose as for MEC [11]. There is no need for routine prophylaxis
for chemotherapy with minimal emetic risk [8,11].
5.2. Management of breakthrough and refractory AINV
Case 4 part 1. A 15-year-old boy weighing 35 kg (BSA 1.2) with
osteosarcoma of femur was planned for ﬁrst cycle of neoadjuvant
chemotherapy with methotrexate, doxorubicin and cisplatin. The cycle
involved administration of cisplatin and doxorubicin on days 1 and 2
followed 3 weeks later by high-dose methotrexate. He received cap.
aprepitant 125 mg on day and 80 mg on days 2 and 3; Inj. granisteron
1.4 mg IV once daily as well as Inj. dexamethasone 4 mg 6 hourly
during the chemotherapy block. Despite prophylaxis, he developed
debilitating vomiting from night of day 1. He remained admitted for 2
days after completion of chemotherapy for intravenous hydration as
he had continuous vomiting and almost nil oral intake.
Case 4 exempliﬁes a case of breakthrough AINV, that occurs in
the acute/delayed phase despite adequate prophylaxis and not
attributable to any other pathological case. The most important
aspect of AINV management is prevention by providing an
adequate and robust antiemetic prophylaxis [3]. Options for man-
aging breakthrough and refractory AINV are limited. For patients
who experience breakthrough AINV after prophylaxis for LEC/MEC,
the prophylaxis can be escalated to the next higher risk (e.g. pro-
phylaxis recommended for HEC can be given to a child who de-
velops breakthrough AINV after prophylaxis recommended for
MEC) [4]. If a patient has already received complete prophylaxis as
recommended for HEC, olanzapine is a reasonable option [4]. An
adult phase 2 trial has demonstrated safety and effectiveness of
olanzapine in breakthrough AINV [25]. Although prospective data is
lacking, a retrospective multi-centric review of pediatric use of
olanzapine for AINV demonstrated up to 65% control of AINVwith a
single daily dose of 0.1 mg/kg/day and no major adverse events
other than dose related sedation [26]. Other less frequent adverse
events which are reversible and minor include extrapyramidal
symptoms and ECG changes [4]. IV administration is not recom-
mended. Due to metabolism by CYP1A2 enzyme, its use is
discouraged in patients receiving drugs which inhibit/induce the
enzyme such as carbamazepine, rifampicin and ciproﬂoxacin [4].
Alternatives for patients who are not eligible to receive olanzapine
include levomepromazine and metoclopramide [4]. Levomepro-
mazine is recommended at a dose of 0.25mg/kg/day in 2e3 divided
doses [maximum 40 mg/day] but experience in children is lacking
[4]. Metoclopramide is a reasonable option in children who have
completed 1 year of age (Dose described earlier) [4].
AINV is said to be refractory if AINV ensues in a patient during
acute/delayed phase subsequent to an episode of breakthrough
AINV in the prior block of chemotherapy. In other words, AINV
occurs despite prophylaxis as well as prior management of break-
through AINV [4]. Once again, the option of escalating prophylaxis
is available for patients who have received prophylaxis for MEC/LEC
[4]. If prophylaxis has already been for HEC, the POGO guidelinerecommends changing 5HT3-R antagonist from ondansetron/gra-
nisetron to palonosetron [4]. Palonosetron is approved for children
aged >1 month at a single stat dose of 20 mg/kg (maximum 1.5 mg)
infused IV over 15 min, 30 min prior to start of chemotherapy [27].
If palonosetron is unavailable, one can consider switching from
ondansetron to granisetron, as some individuals may have rapid
metabolism of ondansetron due to enzyme polymorphisms [4].
Case 4 part 1management: The boy had already received complete
prophylaxis for HEC. Olanzapine was added at dose of 5 mg PO daily.
Vomiting reduced signiﬁcantly albeit with some drowsiness after
starting the drug. After 3 days, olanzapine was stopped and he was
discharged.
5.3. Management of anticipatory AINV
Case 4 part 2. The same patient described in Case 4 was scheduled
for next cycle of chemotherapy. He developed nausea and retching
from the evening previous to hospital visit. Vomiting ensued even as he
entered the hospital premises and prior to starting chemotherapy.
The scenario presented above is characteristic of anticipatory
AINV which precedes administration of chemotherapy, and is
predominantly attributed to the AINV experienced in acute/delayed
phase of the prior chemotherapy blocks [5,7]. It may be triggered by
sights, sounds, odors, thoughts and anxiety associated with the
prior chemotherapy experience, similar to a conditioned response
[3]. It is evident that, greater the control of AINV during acute/
delayed phase, lesser would be the chance of developing antici-
patory AINV. An important aspect of ensuring optimal antiemetic
prophylaxis is following a standard guideline for all patients. A
recently published survey which evaluated the practice of pre-
scribing antiemetic prophylaxis within the Children's oncology
group (COG), reported signiﬁcant diversity among the COG sites
[28]. Differences were especially noted in dosing of dexametha-
sone, choice of anti-emetics when steroids were contraindicated,
aprepitant use in children <12 years and use of aprepitant
concomitantly with drugs with known interactions [28].
Once anticipatory AINV ensues, limited options include two
doses of lorazepam 0.04e0.08 mg/kg PO (maximum 2 mg)
administered the night prior to the day of chemotherapy as well as
the next day morning prior to start of chemotherapy [5]. Though
evidence for its use in AINV is lacking, there is extensive experience
for the safe use of lorazepam in pediatric patients [5]. Non phar-
macological measures such as hypnosis and systemic desensitiza-
tion have also shown beneﬁt, and may be attempted in centers
possessing necessary resources and skills [5].6. Non pharmacological interventions in AINV
Pharmacological intervention does not constitute the sole
aspect of managing AINV. Dietary counseling is important. Some
useful dietary advice includes: consumption of ‘mini meals’
(frequent and small quantities); avoiding strong aromas/odors in
food; drinking liquids from closed containers through straws;
avoiding excessively salty, sweet, spicy or greasy food; sitting for at
least an hour after eating and timing anti-emetics prior to meals
[11,29]. Favorite food items are better avoided during chemo-
therapy blocks. Adult studies have shown role for citrus extracts
and ginger in reducing AINV [30].
Several non-pharmacological interventions can be tried in
children, especially in those who have anticipatory and refractory
AINV. These include: hypnosis, acupuncture, acupressure, guided
imagery, music therapy, progressive muscle relaxation techniques
and psychoeducational support [5,11,30]. These may beneﬁt only a
proportion of children but carry minimal risk of adverse events.
S. Totadri / Pediatric Hematology Oncology Journal 1 (2016) 50e55 557. Conclusion
Accurate prescription of anti-emetics is critical to ensure opti-
mum control of AINV in children. Encouraging evidence for the use
of aprepitant in younger children is emerging. Adherence to stan-
dard guidelines can facilitate adequate prophylaxis and prevent
breakthrough and anticipatory AINV.
Source of funding
Nil.
Competing interest
Nil.
Acknowledgements
Dr. Deepak Bansal (Professor, Hematology-Oncology, Advanced
Pediatric Center, PGIMER, Chandigarh) is gratefully acknowledged
for his suggestions and contribution of literature for the review.
References
[1] Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL, et al.
Symptom assessment in children receiving cancer therapy: the parents'
perspective. Support Care Cancer 2010;18:281e99.
[2] Jordan K, Sippel C, Schmoll H-J. Guidelines for antiemetic treatment of
chemotherapy-induced nausea and vomiting: past, present, and future rec-
ommendations. Oncol 2007;12:1143e50.
[3] Dewan P, Singhal S, Harit D. Management of chemotherapy-induced nausea
and vomiting. Indian Pediatr 2010;47:149e55.
[4] Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, et al.
Guideline for the treatment of breakthrough and the prevention of refractory
chemotherapy-induced nausea and vomiting in children with cancer. Pediatr
Blood Cancer 2016;63:1144e51.
[5] Dupuis LL, Robinson PD, Boodhan S, Holdsworth M, Portwine C, Gibson P, et al.
Guideline for the prevention and treatment of anticipatory nausea and
vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood
Cancer 2014;61:1506e12.
[6] Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008;14:85e93.
[7] Flank J, Dupuis LL. Comparative effectiveness research in antineoplastic-
induced nausea and vomiting control in children. J Comp Eff Res 2014;3:
185e96.
[8] Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S, Lyman GH. Antiemetics:
American society of clinical oncology clinical practice guideline update.
J Oncol Pract 2011;7:395e8.
[9] Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al.
Antiemetics: American society of clinical oncology focused guideline update.
J Clin Oncol 2016;34:381e6.
[10] Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, et al. Guideline
for the classiﬁcation of the acute emetogenic potential of antineoplastic
medication in pediatric cancer patients. Pediatr Blood Cancer 2011;57:191e8.
[11] Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, et al.
Guideline for the prevention of acute nausea and vomiting due toantineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer
2013;60:1073e82.
[12] Search Drug Information, Interactions, Images, Dosage & Side Effects j CIMS
India [Internet]. [cited 2016 Aug 8]. Available from: http://www.mims.com/.
[13] Vidall C, Fernandez-Ortega P, Cortinovis D, Jahn P, Amlani B, Scotte F. Impact
and management of chemotherapy/radiotherapy-induced nausea and vom-
iting and the perceptual gap between oncologists/oncology nurses and pa-
tients: a cross-sectional multinational survey. Support Care Cancer 2015;23:
3297e305.
[14] Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I,
Nortier JWR, et al. Anti-emetic drugs in oncology: pharmacology and indi-
vidualization by pharmacogenetics. Int J Clin Pharm 2011;33:33e43.
[15] Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann
Oncol Off J Eur Soc Med Oncol ESMO 2010;21:2316e23.
[16] Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the
prevention of chemotherapy-induced nausea and vomiting in children: a
randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:385e94.
[17] Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an
add-on therapy in children receiving highly emetogenic chemotherapy: a
randomized, double-blind, placebo-controlled trial. Support Care Cancer
2015;23:3229e37.
[18] FDA approval for oral suspension of aprepitant.pdf [Internet]; [cited 2016 Aug
4]. Available from: http://www.accessdata.fda.gov/drug satfda_docs/label/
2015/207865lbl.pdf.
[19] Howell JE, Szabatura AH, Hatﬁeld Seung A, Nesbit SA. Characterization of the
occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
J Oncol Pharm Pract 2008;14:157e62.
[20] Durand J-P, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1
antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol
2007;18:808e9.
[21] POGO_Acute_AINV_Full_Guideline_Feb_28_2013pdf [Internet]. [cited 2016
Aug 4]. Available from: http://www.pogo.ca/_media/File/guidelines/POGO_
Acute_AINV_Full_Guideline_Feb_28_2013.pdf.
[22] K€oseoglu V, Kürekçi AE, Sarici U, Atay AA, Ozcan O, Sorici U. Comparison of the
efﬁcacy and side-effects of ondansetron and metoclopramide-
diphenhydramine administered to control nausea and vomiting in children
treated with antineoplastic chemotherapy: a prospective randomized study.
Eur J Pediatr 1998;157:806e10.
[23] Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of
metoclopramide in children: a systematic review and meta-analysis. Drug Saf
2016;39:675e87.
[24] Metoclopramide Full Prescribing Information, Dosage & Side Effects j CIMS
India [Internet]. [cited 2016 Aug 4]. Available from: http://www.mims.com/
india/drug/info/metoclopramide/?type¼full&mtype¼generic#Dosage.
[25] Chanthawong S, Subongkot S, Sookprasert A. Effectiveness of olanzapine for
the treatment of breakthrough chemotherapy induced nausea and vomiting.
J Med Assoc Thai 2014;97:349e55.
[26] Flank J, Thackray J, Nielson D, August A, Schechter T, Alexander S, et al.
Olanzapine for treatment and prevention of acute chemotherapy-induced
vomiting in children: a retrospective, multi-center review. Pediatr Blood
Cancer 2015;62:496e501.
[27] aloxi - pipdf [Internet]. [cited 2016 Aug 5]. Available from: http://www.aloxi.
com/docs/pdf/pi.pdf.
[28] Patel P, Robinson PD, Orsey A, Freedman JL, Langevin A-M, Woods D, et al.
Chemotherapy-induced nausea and vomiting prophylaxis: practice within the
Children's oncology group. Pediatr Blood Cancer 2016;63:887e92.
[29] Nutrition for Children with Cancer [Internet]. [cited 2016 Aug 5]. Available
from: http://www.cancer.org/treatment/childrenandcancer/whenyourchild
hascancer/nutritionforchildrenwithcancer/index.
[30] Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. Alternative methods to treat
nausea and vomiting from Cancer chemotherapy. 818759 Chemother Res
Pract 2015;2015. http://dx.doi.org/10.1155/2015/818759. Epub 2015 Nov 8.
